UK private sector shrinks as export orders slump; state borrowing nearly £15bn above official forecast – business live | Business




Slump in export orders pushes UK private sector into decline

The UK’s private sector went into decline for the first time in 1 1/2 years, as new export orders fell at the fastest rate in almost five years, in a sign that trade wars are taking their toll on the British economy.

Weaker demand from international markets weighed on business activity in both the manufacturing and service sectors, according to a closely watched survey.

At 48.2 in April, down from 51.5 in March, the headline ‘flash’ reading from S&P Global was below the 50 mark (that separates expansion from contraction) for the first time since October 2023. While signalling only a modest rate of decline, the latest reading was the lowest since November 2022.

Firms talked about the negative impact of US tariffs and a subsequent slump in confidence among clients. Optimism about the year ahead also slumped, to its lowest level since October 2022.

Many companies flagged concerns about worsening global economic prospects in the wake of US tariffs, as well as subdued confidence regarding the outlook for domestic business conditions.

Service providers recorded a slight decline in business activity during April, which ended a 17-month period of expansion. Rising global economic uncertainty and subdued domestic demand conditions were cited as the main factors.

Manufacturers recorded a fall in production volumes for the sixth successive month. The latest decline was the steepest since August 2022 and widely attributed to weakening market conditions, especially in key export markets.

Peel Hunt’s chief economist Kallum Pickering said:

Share

Updated at 

Key events

AstraZeneca boss joins other pharma CEOs in calling for higher drug spending in Europe

AstraZeneca boss Pascal Soriot has added his voice to other European pharmaceutical bosses calling for higher spending on medicines in Europe.

The world order is shifting right now and Europe needs to invest more in what really matters to it. Europe has stepped up to invest more in defence and now it must protect its health sovereignty.

Europe spends a substantially lower share of GDP on innovative medicines than the US and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk.

The chief executives of Swiss drugmaker Novartis and France’s Sanofi have called on the EU to increase drug prices to bring them more into line with those paid by the US, arguing it will encourage innovation –- i.e. the development of new treatments.

Several major European pharma companies have announced total investments of more than $150bn in the US in recent weeks, at least in part intended to head off potentially punitive Donald Trump tariffs. The latest was Switzerland’s Roche with a $50bn investment in US manufacturing over the next five years unveiled yesterday.

In a letter to the Financial Times published today, Novartis CEO Vas Narasimhan and Sanofi’s Paul Hudson, argue that the European Commission should set a spending target for medicines and vaccines to “fairly reward innovation”.

European price controls and austerity measures reduce the attractiveness of its markets. Launch prices are suppressed, patented medicines’ growth capped, and prices reduced when new applications are found. The US and China are finding ways to incentivise innovation, while Europe is penalising it.

The US pays nearly three times as much for branded and generic medicines as other comparable countries, according to US government estimates.

The EU should create a Europe-wide list price for medicines “within range of US net prices”, the pharma bosses say, adding that this could be adjusted though rebates for some countries. Secondly, they argue that the EU should also set a Europe-wide spend target for innovative medicines and vaccines.

The letter points to data that 30% of medicines approved in the US are still not available in Europe after two years. Narasimhan and Hudson add:

Over time it is inevitable that clinical trials and R&D [research & development] will further shift to the US and China.

The letter comes after pharma bosses wrote to European commission president Ursula von der Leyen earlier this month to warn that “unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US”.

AstraZeneca Pascal Soriot. Photograph: Justin Tallis/PA

The EU’s average government spending on health in 2022 was 7.7% of GDP. By comparison, the US spent 16.5% of its GDP on healthcare in 2023.

Share

Updated at 



Source link

Posted: 2025-04-23 14:27:26

New John Lennon documentary film on his final decade after Beatles gets trailer | Films | Entertainment
 



... Read More

Wimbledon finalist presented £11 gift card in parking garage after winning odd tournament | Tennis | Sport
 



... Read More

England player ratings vs Albania with one 9/10 in Tuchel's first match | Football | Sport
 



... Read More

Wetherspoon worker reveals ‘freshest’ thing to order from the menu
 



... Read More

What Trump's push to shut U.S. Dept. of Education means for students and schools
 



... Read More

Edmonton Oilers tap Calvin Pickard for Game 3 start against L.A. Kings
 



... Read More

Hopeful snackers hunted for coveted square Doritos - worth £10,000
 



... Read More

Hollywood star unrecognisable as King Herod in Massacre of the Innocents trailer | Films | Entertainment
 



... Read More